Showing results (171-180 of 195) with videos related to

Sort By:
Pageof 20
Circulation|December 1, 1994
End-systolic volume and long-term survival after coronary artery bypass graft surgery in patients with impaired left ventricular functionA W Hamer, M Takayama, K A Abraham, et al.
Journal of Environmental Monitoring : JEM|July 10, 2012
Bioaccumulation and related effects of PCBs and organochlorinated pesticides in freshwater fish Hypostomus commersoniD Bussolaro, F Filipak Neto, A Glinski, et al.
Bulletin Du Cancer|January 1, 1988
[Intensive chemotherapy and bone marrow grafting during the consolidation phase of stage IV neuroblastoma]T Philip, J M Zucker, J L Bernard, et al.
Neuro-Chirurgie|May 21, 2019
Long term surgical results of 154 petroclival meningiomas: A retrospective multicenter studyF Bernard, L Troude, S Isnard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1996
A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTCP Fumoleau, B Chevallier, P Kerbrat, et al.
Gastroenterologie Clinique Et Biologique|September 12, 2008
Quality control of colonoscopy procedures: a prospective validated method for the evaluation of professional practices applicable to all endoscopic unitsR Coriat, E Pommaret, A Chryssostalis, et al.
Journal of Visceral Surgery|April 26, 2020
Reform of the 3rd cycle in surgery trainingO Farges, C Bertolus, H Thomazeau, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 4, 2009
Factors predicting the sentinel node metastases in T1 breast cancer tumor: an analysis of 1416 casesJ Capdet, P Martel, H Charitansky, et al.
Bulletin Du Cancer|January 1, 1988
[The reproduction in France of Rosen's protocol for osteosarcomas]M Brunat-Mentigny, M C Demaille, E Quitana, et al.
Melanoma Research|February 8, 2000
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies GroupH Cure, P Souteyrand, R Ouabdesselam, et al.
Pageof 20